Budesonide (Jorveza®) accepted for restricted use within NHS Scotland for treatment of eosinophilic esophagitis

Approval is restricted to patients unsuccessfully treated with proton pump inhibitors (PPI) and based on an RCT which demonstrated superiority of budesonide vs placebo in inducing clinico-histologic remission in eosinophilic esophagitis, refractory to treatment with a PPI.

Source:

Scottish Medicines Consortium